TABLE 1

Biodistribution of 111In-DOTA-Z09591 at 2 Hours After Injection in BALB/C nu/nu Mice Bearing U-87 MG Xenografts

Total injected dose (μg)
Organ0.10.5170
Blood0.34 ± 0.050.35 ± 0.070.26 ± 0.040.14 ± 0.02
Lung0.8 ± 0.20.72 ± 0.080.7 ± 0.20.21 ± 0.02
Liver0.99 ± 0.07 *0.84 ± 0.070.8 ± 0.10.39 ± 0.05
Spleen1.8 ± 0.42.0 ± 0.31.6 ± 0.20.25 ± 0.06
Stomach1.1 ± 0.31.0 ± 0.20.8 ± 0.20.19 ± 0.02
Colon1.3 ± 0.31.5 ± 0.21.1 ± 0.40.23 ± 0.05
Kidney288 ± 15267 ± 40256 ± 19310 ± 32
Tumor5.6 ± 1.16.5 ± 0.97.2 ± 2.40.89 ± 0.04
Muscle0.4 ± 0.10.4 ± 0.10.3 ± 0.10.07 ± 0.02
Bone0.6 ± 0.10.8 ± 0.20.6 ± 0.10.14 ± 0.05
GI tract1.2 ± 0.21.7 ± 0.71.2 ± 0.20.50 ± 0.13
  • * Significant difference (P < 0.05) between doses 0.1 and 0.5 μg.

  • Significant difference (P < 0.05) between doses 0.1 and 1 μg.

  • Data for GI tract are presented as %ID per whole sample.

  • Uptake in all organs and tissues, except kidneys, after injection of 70 μg of 111In-DOTA-Z09591 was significantly lower than after injection of any other dose. Data are presented as average %ID/g and SD for 4 mice.